Alnylam Responds to Tekmira Suit

Alnylam Pharmaceuticals (NASDAQ: ALNY), the Cambridge, MA-based developer of RNA interference drugs, said today it has filed a legal response and counterclaim against Vancouver, BC-based Tekmira Pharmaceuticals, which accused Alnylam last month of misappropriating trade secrets. Alnylam president Barry Greene said in a statement that the company plans to “fully defend itself.”

Trending on Xconomy